3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
5
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
52
Myelodysplastic Syndromes
25
Multiple Myeloma
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Leukemia
23
Lymphoma
22
Lymphoma, Non-Hodgkin
21
Leukemia, Lymphocytic, Chronic, B-Cell
21
Melanoma
19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Neoplasms
13
Hodgkin Disease
13
Neoplasm Metastasis
12
Recurrence
11
Hematologic Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
9
Skin Neoplasms
8
Neoplasms, Plasma Cell
8
Myeloproliferative Disorders
8
Lymphoma, Mantle-Cell
8
Lymphoma, Follicular
8
Lymphoma, B-Cell
8
Kidney Neoplasms
8
Ovarian Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Burkitt Lymphoma
7
Carcinoma, Renal Cell
6
Triple Negative Breast Neoplasms
5
Primary Myelofibrosis
5
Anemia, Refractory, with Excess of Blasts
5
Interventions
Rituximab
24
Cyclophosphamide
10
fludarabine phosphate
8
Bortezomib
7
Lenalidomide
6
Tacrolimus
5
Mycophenolic Acid
5
idelalisib
4
ibrutinib
4
Peripheral Blood Stem Cell Transplantation
4
Antilymphocyte Serum
4
tanespimycin
3
Whole-Body Irradiation
3
Radiotherapy
3
Indium
3
Dasatinib
3
Cyclosporine
3
pomalidomide
2
ofatumumab
2
nelarabine
2
ibritumomab tiuxetan
2
Vincristine
2
Sirolimus
2
Radiation
2
Prednisone
2
Polymerase Chain Reaction
2
Methotrexate
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Waldenstrom Macroglobulinemia
×
fludarabine
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts